Once-Yearly Lenacapavir PrEP a Safe, Promising Alternative to Twice-Yearly Dosing

Once-Yearly Lenacapavir PrEP a Safe, Promising Alternative to Twice-Yearly Dosing

(MedPage Today) -- SAN FRANCISCO -- A once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of plasma concentrations compared with twice-yearly subcutaneous lenacapavir for HIV pre...

Researchers develop method to identify dormant cells that carry HIV

Study findings provide a new gene pathway for potential treatment of the virus affecting millions.

Hope for HIV prevention: Annual injection completes important safety trial

Uganda: Annual HIV Prevention Jab Shows Promise - What It Means for Uganda

A groundbreaking annual injection designed to protect against HIV has successfully passed its first safety trial, bringing new hope for long-term prevention.

For more than 40 years, research into the HIV virus has been carried out worldwide. Successful in many ways. Fighting against certain pitfalls of the pathogen and prejudices are still taking place today.

Gilead Sciences has presented at the Conference on Retrovirus and Opportunist Infections (CROI) 2025 new data and several oral presentations on its HIV treatment portfolio. The findings reflect a broad portfolio and a rapidly evolving development line, with the aim of expanding therapeutic options and improving outcomes in people with HIV, maintaining the goal of achieving a cure. “Gilead is driving the next wave of innovation in HIV to help end…